Clinical trials recruiting for Pancreas Cancer
86
Recruiting trials
30
US states with sites
25
Countries
6%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 12 |
| California | 10 |
| Florida | 7 |
| Massachusetts | 7 |
| Texas | 7 |
| Ohio | 6 |
| Missouri | 5 |
| Pennsylvania | 5 |
| Tennessee | 5 |
| Arizona | 4 |
| Maryland | 3 |
| Michigan | 3 |
Top cities
New York, New York 11Boston, Massachusetts 7Los Angeles, California 6Houston, Texas 5La Jolla, California 5St Louis, Missouri 5Jacksonville, Florida 4Nashville, Tennessee 4Philadelphia, Pennsylvania 4Tampa, Florida 4
Self-screener
Recruiting trials
- A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring
- A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients
- Assessing Pancreatic Fistula Rates After Distal Pancreatectomy Using AEON Endostapler
- Autologous CAR-T Cells Targeting B7-H3 in PDAC
- Axelopran for Advanced Cancer in Patients Receiving Opioids
- Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
- CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
- CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
- Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
- Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening
- Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
- Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
- Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
- Collection of Circulating Biomarkers in Pancreatic Cancer
- Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker
- Compliance With ERAS Protocol in Pancreatic Surgery, Stress Response and Outcomes
- Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
- Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma
- Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts
- EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
- Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
- Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
- Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
- ExoLuminate Study for Early Detection of Pancreatic Cancer
- Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
- GPC3/Mesothelin-CAR-γδT Cells Against Cancers
- Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
- Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
- Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
- Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
- MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
- Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
- Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
- MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
- Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
- Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
- Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
- Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
- PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
- Pancreas Registry and High Risk Registry
- Pancreatic Cancer Early Detection Consortium
- Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX
- Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate
- Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
- Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy
- Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery
- Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
- Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer
- Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy
- Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas
- Prognostic Factors in Periampullary Tumors and Cysts
- Promoting CT Engagement for Pancreatic Cancer With App
- Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)
- Reinforced Pancreaticojejunostomy With or Without glubran2
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)
- Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
- Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
- Stereotactic Magnetic Resonance Guided Radiation Therapy
- Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
- Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
- Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
- Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
- The Cancer of the Pancreas Screening-5 CAPS5)Study
- The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy
- The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer
- Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Use of Ctdna in Patients With Gastrointestinal Tract Tumors
- Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
- ctDNA Assay in Patients With Resectable Pancreatic Cancer
- tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Related conditions
Trials recruiting for Pancreas Cancer often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870Lung cancer 2180Colorectal cancer 1359Breast cancer 2239Gastric cancer 91Colon cancer 96Prostate cancer 1234Pancreas Adenocarcinoma 19Ovarian cancer 118Liver cancer 43
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Pancreas Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.